ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Hepatitis B Data at AASLD 2022 October 24, 2022 12:50 PM Eastern Daylight Time CONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure in patients chronically infected with Hepatitis B, [...]
ClearB Therapeutics Announces Acceptance of Abstract Highlighting Pre-Clinical Chronic Hepatitis B Data as a Poster Presentation at EASL 2022 June 15, 2022 09:16 AM Eastern Daylight Time CONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure of hepatitis [...]
Impact of various expression systems on efficacy of HBsAg therapeutic vaccines to achieve clearance in a mouse model of chronic hepatitis B ClearB Therapeutics, Inc., a company developing a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that its abstract titled “Impact [...]
June 21, 2021 ClearB Therapeutics Announces Acceptance of Abstract Highlighting New Pre-Clinical Hepatitis B Data as a Poster Presentation at EASL 2021 CONCORD, Mass. & MELBOURNE, Australia--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that its abstract [...]
Aliquam sit amet ipsum eu tellus tincidunt commodo. Aenean metus tellus, vehicula at nisl vel, laoreet gravida risus. Integer nec fringilla neque. Vivamus tincidunt dui vitae augue.
Suspendisse maximus, quam eget gravida consectetur, mauris urna porta velit, egestas facilisis augue arcu vitae magna. Curabitur rutrum augue augue, non sodales eros porttitor.
Integer molestie eros at urna sodales pharetra quis vitae diam. Sed quis dui ultrices, suscipit eros quis, faucibus eros. Vivamus lectus nisl, malesuada nec viverra eu, facilisis ut odio.
